Skip to main content
. 2015 Feb 15;8(2):2289–2298.

Table 1.

Summery table of the meta-analysis

Author Year Country Study design Recruitment period Age (median) Case Treatment setting Measurement Cutoff High expression of VEGF Survival analysis
Wang Q 2013 China Retrospective 1982-2007 34-85 (65.83) 148 Prostatectomy IHC Low VS high 98 CSS
Vergis R 2008 UK Prospective 1995-2002 50-80 (67) 201 Radiotherapy IHC Low VS high 34 BF
Vergis R 2008 UK Prospective 1995-2005 45-78 (61) 278 Prostatectomy IHC Low VS high 14 BF
West AF 2001 UK Prospective 1989-1994 49-90 57 Prostatectomy IHC Low VS high 32 CSS
Shariat SF 2004 USA Prospective 1994-1995 40-80 (62.6) 215 Prostatectomy ELISA 9.9 pg/ml _ PFS
Pan L 2013 Canada Retrospective -1991 55-81 (71) 103 Radiotherapy IHC 0-1 vs. 2-3 54 OS DFS BF
George DJ 2001 USA Prospective 1996-1998 62-75 (68) 197 Hormone therapy ELISA 260 pg/ml 16 OS
Bok RA 2001 USA Prospective _ 63-76 (70) 100 Hormone therapy urine ELISA 28 pg/ml 50 OS
Green MM 2007 UK Retrospective 1995-2000 _ 50 Radiotherapy IHC Low VS high 28 CSS
Peyromaure M 2007 France Prospective 2005.06-11 57-68 (62) 89 Prostatectomy IHC Low VS high 36 PFS
Fukuda H 2007 Japan Retrospective 1997-2003 5-83 (71) 58 Prostatectomy IHC Low VS high _ PFS
Weber DC 2012 Switzerland Prospective 1994-2004 56-81 (69.1) 103 Radiotherapy IHC Low VS high 76 PFS
Mori R 2010 USA Retrospective 1972-1999 _ 138 Prostatectomy PCR 10.35 44 OS DFS BF

Abbreviations: CSS, cancer-specific survival; PFS, progression-free survival; OS, overall survival; DFS, disease-free survival; BF, biomedical failure; IHC, immunohistochemistry; ELISA, enzyme-linked immunosorbent assay; PCR, polymerase chain reaction; (-), not reported.